Infant with Rare Genetic Disease Saved for First Time in History Using Personalized CRISPR Therapy
American doctors achieved a breakthrough by applying individualized in vivo gene editing to treat a child with an extremely rare condition. This case paves the way for creating drugs tailored to a specific patient, turning genetic engineering into a precision weapon against incurable diseases.
They Edited a Baby's Genes in 6 Months. This Is the End of 'One-Size-Fits-All' Medicine
Kyle Muldoon and Nicole gave birth to their son KJ in August 2024. Within days, the baby began refusing food, his body became limp, and his blood ammonia levels soared to toxic values that typically mean irreversible brain damage or death. The diagnosis: severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, an ultra-rare glitch in a single 'sentence' of DNA that prevents the liver from processing protein into safe waste. The odds of surviving until a transplant were 50-50, and only if the child could be kept on the brink of a coma long enough. On February 25, 2025, seven-month-old KJ received an infusion of lipid nanoparticles loaded with a molecular editor created specifically for him. He became the first person in history to receive a personalized CRISPR therapy in vivo—directly into the bloodstream, without removing cells from the body.
Not a 'Drug for a Disease,' but a 'Drug for One Patient'
Until now, gene therapy has worked on a blockbuster logic: find a mutation that thousands of people have, build one construct, and sell it as a product. That's how Casgevy works—the FDA-approved CRISPR treatment for sickle cell disease. But KJ had a 'private' mutation not found anywhere else in the world. No pharmaceutical company would develop a therapy for a market of one. The team of Rebecca Ahrens-Nicklas and Kiran Musunuru from Children's Hospital of Philadelphia and Penn Medicine decided to take a different path: not to create a product, but to build a pipeline.
In six months—from mutation identification to first infusion—they designed a guide RNA targeting the single 'typo' in KJ's gene, packaged a base editor into lipid nanoparticles using the same platform as mRNA vaccines, conducted preclinical tests on the patient's cells, and obtained regulatory approval under the expanded access protocol—the same 'compassionate use' that allows treating hopeless patients with experimental agents.
Result: after three infusions (February–April 2025), KJ began tolerating dietary protein, the dose of nitrogen-scavenging drugs was halved, and crucially, his ammonia levels stopped spiking during common childhood colds. The child, who was predicted to have lifelong disability or death, started walking and talking.
From 'Milasen' to 'Plausible Mechanism': Why the System Broke Open Now
The story of personalized gene therapy didn't start with CRISPR. In 2017, seven-year-old Mila Makovec received an individualized antisense oligonucleotide (ASO), named milasen in her honor. Her mother founded a nonprofit, raised $3 million, and a team at Boston Children's Hospital designed the drug in a month. Mila lived another three years—Batten disease ultimately won, but the precedent was set.
That story exposed the main problem: access to N-of-1 therapies depended on crowdfunding and the parents' social capital. If you couldn't raise millions on social media, your child died. The clinical trial system simply wasn't designed for a single patient: a randomized controlled trial requires hundreds of participants, and for ultra-rare diseases, they physically don't exist.
On February 23, 2026, exactly one year after KJ's infusion, the FDA released a draft guidance that the Ahrens-Nicklas and Musunuru team helped shape. The document is called the 'Plausible Mechanism Framework'—and it is, without exaggeration, the most radical regulatory reform in personalized medicine in 25 years. The gist: if you can prove that the therapy precisely targets the biological cause of the disease, and the natural history of the disease is well documented, positive results in 5–10 patients may suffice for platform approval. Moreover, different editor variants targeting different mutations in the same gene can now be registered as a single drug.
Vinay Prasad, director of CBER, called it a 'revolutionary breakthrough in regulatory science.' Marty Makary, FDA commissioner, promised to 'remove barriers' for ultra-rare diseases. Elon Musk has nothing to do with it—but the speed at which this passed through the bureaucratic machine is truly unprecedented.
A $12 Billion Market Built Not for Profit
Here's where it gets interesting: the economics. The CRISPR genomic drug market was valued at $3.7 billion in 2024 and is projected to reach $12 billion by 2030—a CAGR of 21.5%. But personalized therapy is not a blockbuster model. You can't sell 'KJ's drug' to anyone else. Pharma giants like Roche and Vertex hunt for indications with thousands of patients, not single mutations.
The paradox is that KJ's case creates the infrastructure that could make individual therapies cheaper than they seem. CHOP already supports over 80 researchers in cell and gene therapy and runs 45 active pediatric trials. The pipeline built for one child is now a reproducible process: sequence the mutation, design the guide RNA, assemble the editor on the same lipid platform, get expanded access in months, not years.
Who loses? The traditional clinical trial model, built for thousands of patients and decade-long timelines. Who wins? Academic medical centers, which can now do what was once the exclusive domain of Big Pharma with multi-billion R&D budgets. CHOP and Penn are already designing 'umbrella' protocols where one editor construct can be tested on patients with seven different urea cycle disorders.
What's Next: CRISPR-on-Demand and the End of 'Orphan' Status
The forecast for the next three years is not vague statements but concrete steps already underway.
First: The FDA will finalize the Plausible Mechanism Framework after a 60-day public comment period. This will happen in April–May 2026, and immediately after, academic centers will begin submitting applications for master protocols targeting classes of mutations, not individual diseases.
Second: Musunuru's team is working to apply the same base editor targeting the CPS1 gene to dozens of children with different mutations in the same gene. This turns N-of-1 into N-of-few, and then into a platform product where the cost per patient drops from millions to hundreds of thousands of dollars.
Third: The ethical question of equitable access hasn't gone away. For now, each such therapy requires heroic efforts from parents and doctors. But if the FDA allows registering a platform rather than an individual drug, insurance companies and Medicare will get a clear billing code. N-of-1 will cease to be charity and become a medical service—expensive, but standardized.
Kiran Musunuru said at the Genome Editing Summit in September 2025 what should be carved above the entrance of every children's hospital: 'We want every patient to have a chance at the same outcomes we saw in the first patient.' The first patient now walks and talks. Six months is the new standard of speed.
— Editorial Team
